Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer
July 20, 2023
Targeted therapy in NSCLC, FCS was part of this trial.
Preoperative Treatment of Locally Advanced Rectal Cancer
July 1, 2023
Paradigm shift in rectal cancer therapy? Some may not need surgery, now some may not need radiotherapy.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
July 1, 2023
CAR-T for second line is better than standard of care, the question is: how about compared to BITE therapy? Future is exciting for those patients.
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
July 1, 2023
High burden prostate cancer patients benefit form androgen deprivation and Taxotere combination.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
July 1, 2023
Combination PARP with androgen blocker, regardless of HRR gene alterations showed benefit vs. androgen blocker alone.
Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases
July 1, 2023
For our radiation oncology colleagues, any comments? For oligometastases, radiation therapy helps improve survival when added to systemic therapy.
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
July 1, 2023
Pembrolizumab in lymphoma, this is not a common one, usually in young females, could be hard to treat.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
July 1, 2023
Luspaterecpt before epoetin in low grade MDS patients.
